中国医药
(600056)
| 流通市值：152.82亿 | | | 总市值：152.88亿 |
| 流通股本：14.95亿 | | | 总股本：14.96亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 8,262,744,582.75 | 34,148,359,638.99 | 26,099,729,998.4 | 17,797,322,228.73 |
| 营业收入 | 8,262,744,582.75 | 34,148,359,638.99 | 26,099,729,998.4 | 17,797,322,228.73 |
| 二、营业总成本 | 7,973,445,487.28 | 32,983,445,215.42 | 25,216,783,611.99 | 17,153,291,092.83 |
| 营业成本 | 7,387,332,882.18 | 30,489,593,937.49 | 23,317,058,605.89 | 15,856,033,265.53 |
| 税金及附加 | 27,489,300.41 | 98,234,876.81 | 68,753,867.61 | 45,944,436.93 |
| 销售费用 | 242,630,292.96 | 1,099,225,919.18 | 836,164,693.31 | 589,386,726.56 |
| 管理费用 | 245,085,700.87 | 975,246,965.38 | 777,491,393.59 | 509,539,878.02 |
| 研发费用 | 33,518,271.97 | 125,219,820.99 | 89,752,947.32 | 63,682,744.87 |
| 财务费用 | 37,389,038.89 | 195,923,695.57 | 127,562,104.27 | 88,704,040.92 |
| 其中:利息费用 | 35,147,574.66 | 205,513,268.09 | 113,574,940.63 | 87,148,230.11 |
| 其中:利息收入 | 12,711,932.65 | 36,891,786.01 | 47,774,014.36 | 22,286,494.14 |
| 加:公允价值变动收益 | 154,794.37 | 127,466,901.01 | -1,108,515.03 | -1,108,515.03 |
| 加:投资收益 | 7,559,129.15 | -65,016,832.54 | 5,002,730.82 | 1,310,642.23 |
| 资产处置收益 | -47,650.36 | 1,653,400.91 | 1,026,006.48 | -102,314.12 |
| 资产减值损失(新) | -2,069,741.33 | -175,325,505.38 | 1,150,416.96 | 1,216,930.7 |
| 信用减值损失(新) | 2,510,401.61 | -187,023,535.26 | -65,698,071.63 | -56,918,894.18 |
| 其他收益 | 7,244,850.21 | 64,899,006.22 | 27,245,720.58 | 18,223,735.46 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 304,650,879.12 | 931,567,858.53 | 850,564,674.59 | 606,652,720.96 |
| 加:营业外收入 | 2,749,688.16 | 45,254,389.89 | 9,766,439.48 | 6,718,433.17 |
| 减:营业外支出 | 2,786,924.59 | 23,633,734.53 | 17,547,335.07 | 9,347,320.68 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 304,613,642.69 | 953,188,513.89 | 842,783,779 | 604,023,833.45 |
| 减:所得税费用 | 77,413,614.06 | 266,564,631.87 | 221,865,802.33 | 154,267,062.99 |
| 六、净利润 | 227,200,028.63 | 686,623,882.02 | 620,917,976.67 | 449,756,770.46 |
| 持续经营净利润 | 227,200,028.63 | 686,623,882.02 | 620,917,976.67 | 449,756,770.46 |
| 归属于母公司股东的净利润 | 166,379,236.02 | 535,467,687.81 | 447,148,326.32 | 325,119,038.69 |
| 少数股东损益 | 60,820,792.61 | 151,156,194.21 | 173,769,650.35 | 124,637,731.77 |
| (一)基本每股收益 | 0.11 | 0.36 | 0.3 | 0.22 |
| (二)稀释每股收益 | 0.11 | 0.36 | 0.3 | 0.22 |
| 八、其他综合收益 | 884,977.29 | -362,481.48 | -3,545,260.38 | -1,457,158.88 |
| 归属于母公司股东的其他综合收益 | 884,977.29 | -383,971.37 | -3,545,260.38 | -1,457,158.88 |
| 九、综合收益总额 | 228,085,005.92 | 686,261,400.54 | 617,372,716.29 | 448,299,611.58 |
| 归属于母公司股东的综合收益总额 | 167,264,213.31 | 535,083,716.44 | 443,603,065.94 | 323,661,879.81 |
| 归属于少数股东的综合收益总额 | 60,820,792.61 | 151,177,684.1 | 173,769,650.35 | 124,637,731.77 |
| 公告日期 | 2025-04-30 | 2025-04-26 | 2024-10-26 | 2024-08-21 |
| 审计意见(境内) | | 标准无保留意见 | | |